Header Logo

Connection

Sunita Gulati to Disease Models, Animal

This is a "connection" page, showing publications Sunita Gulati has written about Disease Models, Animal.
Connection Strength

0.378
  1. Gulati S, Mattsson AH, Schussek S, Zheng B, DeOliveira RB, Shaughnessy J, Lewis LA, Rice PA, Comstedt P, Ram S. Preclinical efficacy of a cell division protein candidate gonococcal vaccine identified by artificial intelligence. mBio. 2023 Dec 19; 14(6):e0250023.
    View in: PubMed
    Score: 0.127
  2. Gulati S, Zheng B, Reed GW, Su X, Cox AD, St Michael F, Stupak J, Lewis LA, Ram S, Rice PA. Immunization against a saccharide epitope accelerates clearance of experimental gonococcal infection. PLoS Pathog. 2013; 9(8):e1003559.
    View in: PubMed
    Score: 0.063
  3. Shaughnessy J, Chabeda A, Tran Y, Zheng B, Nowak N, Steffens C, DeOliveira RB, Gulati S, Lewis LA, Maclean J, Moss JA, Wycoff KL, Ram S. An optimized Factor H-Fc fusion protein against multidrug-resistant Neisseria gonorrhoeae. Front Immunol. 2022; 13:975676.
    View in: PubMed
    Score: 0.029
  4. Lewis LA, Gulati S, Zelek WM, Morgan BP, Song WC, Zheng B, Nowak N, DeOliveira RB, Sanchez B, DeSouza Silva L, Schuurman J, Beurskens F, Ram S, Rice PA. Efficacy of an Experimental Gonococcal Lipooligosaccharide Mimitope Vaccine Requires Terminal Complement. J Infect Dis. 2022 05 16; 225(10):1861-1864.
    View in: PubMed
    Score: 0.029
  5. Chakraborti S, Gulati S, Zheng B, Beurskens FJ, Schuurman J, Rice PA, Ram S. Bypassing Phase Variation of Lipooligosaccharide (LOS): Using Heptose 1 Glycan Mutants To Establish Widespread Efficacy of Gonococcal Anti-LOS Monoclonal Antibody 2C7. Infect Immun. 2020 01 22; 88(2).
    View in: PubMed
    Score: 0.024
  6. Bettoni S, Shaughnessy J, Maziarz K, Ermert D, Gulati S, Zheng B, M?rgelin M, Jacobsson S, Riesbeck K, Unemo M, Ram S, Blom AM. C4BP-IgM protein as a therapeutic approach to treat Neisseria gonorrhoeae infections. JCI Insight. 2019 12 05; 4(23).
    View in: PubMed
    Score: 0.024
  7. Ram S, Gulati S, Lewis LA, Chakraborti S, Zheng B, DeOliveira RB, Reed GW, Cox AD, Li J, St Michael F, Stupak J, Su XH, Saha S, Landig CS, Varki A, Rice PA. A Novel Sialylation Site on Neisseria gonorrhoeae Lipooligosaccharide Links Heptose II Lactose Expression with Pathogenicity. Infect Immun. 2018 08; 86(8).
    View in: PubMed
    Score: 0.022
  8. Ram S, Shaughnessy J, de Oliveira RB, Lewis LA, Gulati S, Rice PA. Gonococcal lipooligosaccharide sialylation: virulence factor and target for novel immunotherapeutics. Pathog Dis. 2017 06 01; 75(4).
    View in: PubMed
    Score: 0.020
  9. Shaughnessy J, Gulati S, Agarwal S, Unemo M, Ohnishi M, Su XH, Monks BG, Visintin A, Madico G, Lewis LA, Golenbock DT, Reed GW, Rice PA, Ram S. A Novel Factor H-Fc Chimeric Immunotherapeutic Molecule against Neisseria gonorrhoeae. J Immunol. 2016 Feb 15; 196(4):1732-40.
    View in: PubMed
    Score: 0.018
  10. Ngampasutadol J, Tran C, Gulati S, Blom AM, Jerse EA, Ram S, Rice PA. Species-specificity of Neisseria gonorrhoeae infection: do human complement regulators contribute? Vaccine. 2008 Dec 30; 26 Suppl 8:I62-6.
    View in: PubMed
    Score: 0.011
  11. Lu Z, Roche MI, Hui JH, Unal B, Felgner PL, Gulati S, Madico G, Sharon J. Generation and characterization of hybridoma antibodies for immunotherapy of tularemia. Immunol Lett. 2007 Oct 15; 112(2):92-103.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.